ResVerlogix talks up chance of buyout offer

Canada's ResVerlogix attracted considerable attention at the recent BIO CEO & Investor forum in New York. CEO Donald McCaffrey was talking up plans to be acquired by a deep-pocket biopharma company, saying he's in talks with seven major pharma outfits. Lead therapy RVX-208 is one of those promising 'good cholesterol' drugs, which has investors pushing up the company's stock price, even though the company hasn't reached the clinic yet. Atherosclerosis is a big target these days, and McCaffrey is betting that the extra focus will translate into an offer it can't refuse. Word of a possible takeover probably hasn't hurt the company's stock price, either.

- here's the report on ResVerlogix from BusinessWeek

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.